These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24015306)

  • 1. Effects of different pulmonary vasodilators on arterial saturation in a model of pulmonary hypertension.
    Becker EM; Stasch JP; Bechem M; Keldenich J; Klipp A; Schaefer K; Ulbrich HF; Truebel H
    PLoS One; 2013; 8(8):e73502. PubMed ID: 24015306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching.
    Chamorro V; Morales-Cano D; Milara J; Barreira B; Moreno L; Callejo M; Mondejar-Parreño G; Esquivel-Ruiz S; Cortijo J; Cogolludo Á; Barberá JA; Perez-Vizcaino F
    PLoS One; 2018; 13(1):e0191239. PubMed ID: 29364918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. sGC stimulation totally reverses hypoxia-induced pulmonary vasoconstriction alone and combined with dual endothelin-receptor blockade in a porcine model.
    Lundgren J; Kylhammar D; Hedelin P; Rådegran G
    Acta Physiol (Oxf); 2012 Nov; 206(3):178-94. PubMed ID: 22682645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats.
    Thorsen LB; Eskildsen-Helmond Y; Zibrandtsen H; Stasch JP; Simonsen U; Laursen BE
    Eur J Pharmacol; 2010 Nov; 647(1-3):147-54. PubMed ID: 20828552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
    Yamamoto K; Tanabe N; Suda R; Sasaki A; Matsumura A; Ema R; Kasai H; Kato F; Sekine A; Nishimura R; Jujo T; Sugiura T; Shigeta A; Sakao S; Tatsumi K
    Respir Investig; 2017 Jul; 55(4):270-275. PubMed ID: 28705306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension.
    Grimminger F; Weimann G; Frey R; Voswinckel R; Thamm M; Bölkow D; Weissmann N; Mück W; Unger S; Wensing G; Schermuly RT; Ghofrani HA
    Eur Respir J; 2009 Apr; 33(4):785-92. PubMed ID: 19129292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension.
    Klinger JR; Thaker S; Houtchens J; Preston IR; Hill NS; Farber HW
    Chest; 2006 Feb; 129(2):417-425. PubMed ID: 16478861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled NO and sildenafil combination in cardiac surgery patients with out-of-proportion pulmonary hypertension: acute effects on postoperative gas exchange and hemodynamics.
    Matamis D; Pampori S; Papathanasiou A; Papakonstantinou P; Tsagourias M; Galiatsou E; Koulouras V; Nakos G
    Circ Heart Fail; 2012 Jan; 5(1):47-53. PubMed ID: 22057829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
    Mouchaers KT; Schalij I; de Boer MA; Postmus PE; van Hinsbergh VW; van Nieuw Amerongen GP; Vonk Noordegraaf A; van der Laarse WJ
    Eur Respir J; 2010 Oct; 36(4):800-7. PubMed ID: 20351034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP; Evgenov OV
    Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension.
    Weimann J; Ullrich R; Hromi J; Fujino Y; Clark MW; Bloch KD; Zapol WM
    Anesthesiology; 2000 Jun; 92(6):1702-12. PubMed ID: 10839922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
    Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
    Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal models related to congenital heart disease and clinical research in pulmonary hypertension.
    Loukanov T; Geiger R; Agrawal R
    Cardiology; 2010; 116(1):18-25. PubMed ID: 20424448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs.
    Evgenov OV; Ichinose F; Evgenov NV; Gnoth MJ; Falkowski GE; Chang Y; Bloch KD; Zapol WM
    Circulation; 2004 Oct; 110(15):2253-9. PubMed ID: 15466650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sildenafil and an early stage of chronic hypoxia-induced pulmonary hypertension in newborn piglets.
    Binns-Loveman KM; Kaplowitz MR; Fike CD
    Pediatr Pulmonol; 2005 Jul; 40(1):72-80. PubMed ID: 15880376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New pulmonary hypertension model in conscious dogs to investigate pulmonary-selectivity of acute pharmacological interventions.
    Mondritzki T; Boehme P; Schramm L; Vogel J; Mathar I; Ellinghaus P; Kolkhof P; Bischoff E; Hüser J; Dinh W; Sandner P; Truebel H
    Eur J Appl Physiol; 2018 Jan; 118(1):195-203. PubMed ID: 29159668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The extracellular signal-regulated kinase is involved in the effects of sildenafil on pulmonary vascular remodeling.
    Zeng Z; Li Y; Jiang Z; Wang C; Li B; Jiang W
    Cardiovasc Ther; 2010; 28(1):23-9. PubMed ID: 20074256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive effect of tadalafil and simvastatin on monocrotaline-induced pulmonary hypertension rats.
    Zhang WH; Liu CP; Zhang YJ; Ji YQ; Lu WX; Zeng Q
    Scand Cardiovasc J; 2012 Dec; 46(6):374-80. PubMed ID: 22971207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?
    Koress C; Swan K; Kadowitz P
    Curr Hypertens Rep; 2016 Apr; 18(5):42. PubMed ID: 27118316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose response of intravenous sildenafil on systemic and regional hemodynamics in hypoxic neonatal piglets.
    Haase E; Bigam DL; Cravetchi O; Cheung PY
    Shock; 2006 Jul; 26(1):99-106. PubMed ID: 16783205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.